Article Text

Download PDFPDF

2022-RA-647-ESGO Real-word therapy and clinical and patient-reported outcomes in patients with newly diagnosed advanced ovarian cancer: first description of the SCOUT-1 study centers (NOGGO ov54, NCT04830709)
  1. Jalid Sehouli1,2,
  2. Elena Ioana Braicu1,2,
  3. Regina Maria Glowik3,
  4. Klaus Pietzner1,2,
  5. Matthias Rose4,
  6. Pauline Wimberger5,2 and
  7. Theresa Link5
  1. 1Department of Gynaecology, European Competence Center for Ovarian Cancer, Campus Virchow-Klinikum, Charité Medical University, Berlin, Germany
  2. 2North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
  3. 3AstraZeneca, Hamburg, Germany
  4. 4Centre for Internal Medicine and Dermatology, Department of Psychosomatic Medicine, Charité Medical University, Berlin, Germany
  5. 5Department of Gynecology and Obstetrics, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany


Introduction/Background The prospective non-interventional study SCOUT-1 (NOGGO ov54; NCT04830709) investigates clinical real-world management of patients with advanced ovarian cancer in Germany with a special focus on quality of life (QoL) over a study period of seven years.

Methodology All sites initiated through March 2022 were invited to document the cumulative number and characteristics of their OC patients treated in 2021. Details on site type and certification were also collected. The analysis has a descriptive and exploratory character. The variables are summarized using appropriate statistical methods.

Results Until April 1st, 2022, 47 sites provided cumulative data: 36 (77%) full-service hospitals (university hospital, hospital with maximum or specialized care), 3 (6%) base service hospitals, and 8 (17%) office-based (gyneco)oncological sites. Majority of participating sites are certified (gyneco)oncological centres according the German Cancer Society. Each site treated on average 28 patients with 1L OC in 2021, with a large range of 4–127 patients (13% treated < 1 patient/month, 45% 1–2 patients/month and 43% >2 patients/month). The sites mainly diagnosed advanced stage FIGO III or IV disease (74%), serous histology (71%) and high-grade carcinoma (75%). Most patients received cytoreductive surgery. The majority of patients (80%) received and responded to platinum-based chemotherapy.

Conclusion The analysis of cumulative data is in line with other epidemiologic sources in Germany and reflects a potential to enroll a representative cohort of patients with advanced OC in the SCOUT-1 study. Study is ongoing and is open for recruitment.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.